MUSCLE & BACK PAIN RELIEF WITH IBUPROFEN TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

METHOCARBAMOL; IBUPROFEN

متاح من:

TEVA CANADA LIMITED

ATC رمز:

M03BA53

INN (الاسم الدولي):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

جرعة:

500MG; 200MG

الشكل الصيدلاني:

TABLET

تركيب:

METHOCARBAMOL 500MG; IBUPROFEN 200MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

18/40

نوع الوصفة الطبية :

OTC

المجال العلاجي:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

ملخص المنتج:

Active ingredient group (AIG) number: 0248961001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2021-08-12

خصائص المنتج

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE & BACK PAIN RELIEF WITH IBUPROFEN
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED.
Date of Preparation:
30 Novopharm Court,
May 1, 2013
Toronto, Ontario
Canada, M1B 2K9
Control# 164010
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..............